Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)

Dianthus Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$30.6 million for Q3 2025.

• In Q3 2025, Free Cash Flow fell 43.53% year-over-year to -$30.6 million; the TTM figure through Dec 2025 stood at -$82.2 million (down 4.94% YoY), while the FY2024 annual figure was -$78.3 million, down 111.75% from the prior year.
• Free Cash Flow was -$30.6 million for Q3 2025 at Dianthus Therapeutics, down from -$23.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $16.4 million in Q3 2022 to a low of -$30.6 million in Q3 2025.
• Historically, Free Cash Flow has averaged -$15.1 million across 5 years, with a median of -$15.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 208.05% in 2022, then sank 206.08% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$14.4 million in 2021, then soared by 38.51% to -$8.9 million in 2022, then tumbled by 33.6% to -$11.9 million in 2023, then sank by 131.58% to -$27.5 million in 2024, then retreated by 11.23% to -$30.6 million in 2025.
• The last three Free Cash Flow figures came in at -$30.6 million (Q3 2025), -$23.9 million (Q2 2025), and -$27.7 million (Q1 2025), per Business Quant data.